As part of the program, the company will offer CBD products to oncology patients, aiming to reduce costs and expand access for seniors.
|Articles|June 19, 2023
Noid Factoid from Episode 16, Part II
Author(s)Madeline Colli, Megan L'Heureux
Listen to Part II of this Noid Factoid from Nick Jikomes, PhD, the Director of Science & Innovation at Leafly.
Advertisement
Listen as Nick Jikomes, PhD, the Director of Science & Innovation at Leafly, shares a quick Noid Factoid with us!
Don't miss
On this month’s episode, we are joined by Nick Jikomes, PhD, the Director of Science & Innovation at Leafly. Join us as we discuss Nick’s background, his recent ElSohly award for research related to labeling in cannabis, neuroscience, and endocannabinoids.
Hear more of what Nick has to say in the full Noid Knowledge podcast episode:
Advertisement
Related to this article
President Trump signed an executive order directing federal agencies to reclassify cannabis from Schedule I to Schedule III controlled substances.
Our top cannabis news topics this week: Texas medical cannabis, first Native American-owned East Coast cannabis brand, pivoting with hemp manufacturing, low-dose CBD and stress, and alcohol-induced liver disease.
The research analyzed data from the Dog Aging Project, finding prevalence of use for certain conditions and behavior changes over time.
The retrospective observational study examined the effect of cannabis on the risk of alcohol-associated liver disease in patients with alcohol use disorder.
Advertisement
Advertisement